Modeling Combinations of Pre-erythrocytic Plasmodium falciparum Malaria Vaccines.
Despite substantial progress in the control of Plasmodium falciparum infection due to the widespread deployment of insecticide-treated bed nets and artemisinin combination therapies, malaria remains a prolific killer, with over half a million deaths estimated to have occurred in 2013 alone. Recent evidence of the development of resistance to treatments in both parasites and their mosquito vectors has underscored the need for a vaccine. Here, we use a mathematical model of the within-host dynamics of P. falciparum infection, fit to data from controlled human malaria infection clinical trials, to predict the efficacy of co-administering the two most promising subunit vaccines, RTS,S/AS01 and ChAd63-MVA ME-TRAP. We conclude that currently available technologies could be combined to induce very high levels of sterile efficacy, even in immune-naive individuals.
Andrew S
AS
Walker
José
J
Lourenço
Adrian V S
AVS
Hill
Sunetra
S
Gupta
D006801:Humans; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control*; D008962:Models, Theoretical; D034101:Sporozoites / Q000276:immunology; D017778:Vaccines, Combined / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use
D017780:Malaria Vaccines; C577001:RTS,S-AS01 vaccine; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic